{"result": "(\"entity\"<|>AMIODARONA<|>ORGANIZATION<|>Amiodarona is an antiarrhythmic drug with a high iodine content that can cause thyroid dysfunction in 15-20% of cases.)\n##\n(\"entity\"<|>HORMONAS TIROIDEAS<|>ORGANIZATION<|>Hormonas tiroideas are hormones produced by the thyroid gland that regulate metabolism and are affected by amiodarona.)\n##\n(\"entity\"<|>TIROIDITIS DESTRUCTIVA<|>EVENT<|>Tiroiditis destructiva is a type of thyroiditis that can occur as a result of amiodarona treatment, leading to hyperthyroidism.)\n##\n(\"entity\"<|>HIPERTIROIDISMO<|>EVENT<|>Hipertiroidismo is a condition characterized by excessive thyroid hormone production, which can be induced by amiodarona.)\n##\n(\"entity\"<|>HIPOTIROIDISMO<|>EVENT<|>Hipotiroidismo is a condition characterized by insufficient thyroid hormone production, which can also be a result of amiodarona treatment.)\n##\n(\"entity\"<|>BERTALENA L<|>PERSON<|>Bertalena L is an author referenced in the context of managing Graves' ophthalmopathy and related thyroid conditions.)\n##\n(\"entity\"<|>GRAVES<|>EVENT<|>Graves' disease is an autoimmune disorder that leads to hyperthyroidism and is associated with various ocular symptoms.)\n##\n(\"entity\"<|>FIBROSIS<|>EVENT<|>Fibrosis refers to the thickening and scarring of connective tissue, which can occur in the ocular muscles in advanced stages of Graves' disease.)\n##\n(\"entity\"<|>RECEPTORES DE TSH<|>ORGANIZATION<|>Receptores de TSH are thyroid-stimulating hormone receptors that are implicated in the autoimmune response in Graves' disease.)\n##\n(\"entity\"<|>GLUCOCORTICOIDES<|>ORGANIZATION<|>Glucocorticoides are a class of corticosteroids used in the treatment of various conditions, including Graves' ophthalmopathy.)\n##\n(\"relationship\"<|>AMIODARONA<|>HORMONAS TIROIDEAS<|>Amiodarona affects the synthesis and regulation of thyroid hormones, leading to potential dysfunction<|>8)\n##\n(\"relationship\"<|>AMIODARONA<|>HIPERTIROIDISMO<|>Amiodarona can induce hyperthyroidism in some patients due to its high iodine content<|>7)\n##\n(\"relationship\"<|>AMIODARONA<|>HIPOTIROIDISMO<|>Amiodarona can also lead to hypothyroidism in patients, affecting thyroid hormone levels<|>7)\n##\n(\"relationship\"<|>HIPERTIROIDISMO<|>TIROIDITIS DESTRUCTIVA<|>Tiroiditis destructiva can result in hyperthyroidism due to the release of stored thyroid hormones<|>6)\n##\n(\"relationship\"<|>GRAVES<|>FIBROSIS<|>Fibrosis of the ocular muscles can occur in advanced stages of Graves' disease<|>5)\n##\n(\"relationship\"<|>GRAVES<|>RECEPTORES DE TSH<|>Graves' disease involves an autoimmune response against TSH receptors<|>9)\n##\n(\"relationship\"<|>GLUCOCORTICOIDES<|>GRAVES<|>Glucocorticoides are used in the treatment of Graves' ophthalmopathy<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: o:\n\nA. Incremento en la síntesis de hormonas tiroideas.\nB. Puede aparecer tras la suspensión del tratamiento con amiodarona.\nC. Habitualmente el paciente no presenta patología tiroidea previa.\nD. Habitualmente se evidencia disminución de la vascularización en la eco-Doppler tiroidea.\n\n### COMENTARIO\n\nLa amiodarona es un fármaco antiarrítmico con un alto contenido en yodo que causa disfunción tiroidea en un 15-20% de los casos. Puede originar hipotiroidismo, pero también hipertiroidismo, que puede ser de dos tipos. El tipo 1 es una forma de hipertiroidismo inducido por yodo y el tipo 2 es una tiroiditis destructiva. En consecuencia, la opción A es falsa: al ser una tiroiditis destructiva, la tirotoxicosis no es debida a un aumento de la síntesis de hormonas tiroideas, sino a la liberación de las contenidas en el coloide del folículo.\n\nLas otras tres opciones son ciertas. La tirotoxicosis puede aparecer incluso meses después de la suspensión de la amiodarona, debido a que la amiodarona y sus metabolitos tienen una vida media muy larga (más de 100 días). De la misma forma, es cierto que habitualmente se presenta en pacientes sin patología tiroidea previa, a diferencia de la de tipo 1, en la que los pacientes suelen presentar un bocio multinodular o una enfermedad de Graves latente. Asimismo, la imagen con eco-Doppler de la glándula muestra una disminución de su vascularización, a diferencia de la de tipo 1, en la que hay aumento de la vascularización tiroidea.\n\nReferencias:\n- Bogazzi F, Bartalena L, Martino E. Approach to the Patient with Amiodarone-Induced Thyrotoxicosis. J Clin Endocrinol Metab. 2010;95:2529-35.\n- Bogazzi F, Martino E, Dell'Unto E, Brogioni S, Cosci C, Aghini-Lombardi F, et al. Thyroid color flow Doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest. 2003;26:635-40.\n- Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001;22:240-54.\n\n## 14. Señale la afirmación cierta en relación con la oftalmopatía de Graves:\n\nA. El hábito tabáquico no aumenta el riesgo de aparición de oftalmopatía de Graves.\nB. En las fases iniciales de la oftalmopatía de Graves se observa con frecuencia fibrosis de la musculatura ocular extrínseca.\nC. Hay evidencia de aumento de expresión de receptores de TSH en fibroblastos y adipocitos retroorbitarios.\nD. En relación con el tratamiento de la oftalmopatía de Graves, las dosis de glucocorticoides intravenosos superiores a 4 g se asocian frecuentemente con hepatotoxicidad.\n\n### COMENTARIO\n\nExiste una clara y consistente relación entre el hábito tabáquico y la oftalmopatía de Graves, tanto en su frecuencia de aparición como en su gravedad (opción A falsa).\n\nLa aparición de fibrosis en la musculatura ocular aparece en las fases finales de su evolución, después de una fase inicial inflamatoria caracterizada por infiltración linfocitaria y edema de la musculatura ocular (opción B falsa).\n\nLa orbitopatía de Graves es consecuencia del reconocimiento por parte de linfocitos T autorreactivos de un antígeno compartido con el tiroides, lo que origina una reacción inflama-\n---\nTIROIDES     3\n\ntoria. Aunque no está totalmente dilucidado, hay suficiente evidencia de que el antígeno responsable es el receptor de la TSH y que el lugar en el que se expresa, más que en la musculatura extrínseca ocular, es en los adipocitos y fibroblastos orbitarios (opción C correcta).\n\nFinalmente, la opción D no es cierta. Aunque se ha descrito fallo hepático en un 0,8% de los pacientes tratados con dosis elevadas de corticoides, se considera segura su utilización en dosis menores de 8 mg.\n\nReferencias:\n- Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid. 2008;18:333-46.\n- Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168-99.\n- Hegedus L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves' o\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}